Actinium Pharmaceuticals to share new radiotherapy research on ATNM-400 across solid tumors at AACR-NCI-EORTC 2025
Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.
